NCT00532116已完成4 期
Pharmacokinetic Comparison of the 6mg/24hr and 12mg/24hr EMSAM (Selegiline Transdermal System) in Healthy Elderly and Non-Elderly Volunteers
Somerset Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Dose Proportionality of PK parameters and EMSAM release characteristics.
研究概览
简要总结
Evaluate the effect of age on the PK of two different doses of EMSAM.
研究设计
- 研究类型
- Interventional
- 干预模型
- Crossover
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or Female, 18 to 45years of age (inclusive) and 65 years of age or older.
- •Non-obese as defined by being within 15% of desirable body weight for frame size (Appendix II).
- •In general good health as ascertained by physical examination (PE) including measurement of supine and standing vital signs, medical history, clinical laboratory studies, and 12-lead electrocardiogram (ECG).
- •Females must have a negative serum pregnancy test during screening confirmed by a negative urine pregnancy screen at the baseline visit. Women of childbearing potential must agree to continuously use a medically acceptable method of birth control during the course of the study. Acceptable birth control methods are hormonal contraceptives, intrauterine devices or double barrier method (a combination of condom plus contraceptive foam). Postmenopausal females will be eligible to participate if their last normal menses was at least one (1) year prior to study entry.
- •Able and willing to provide informed consent.
- •Able and willing to follow a modified diet.
- •Able and willing to follow the requirements of the study; willing to wear a patch, no swimming, no excessive exercise, etc.
排除标准
- •Presence of significant acute or chronic medical disorder that might complicate or interfere with MAO inhibitor therapy, such as:
- •Any cardiovascular or cardiac condition requiring drug treatment. Upon review with Sponsor, subjects with well controlled hypertension or hyperlipidemia will be allowed.
- •History of symptomatic orthostatic hypotension, or in the investigator's best clinicaljudgment a clinically significant postural decrease in systolic blood pressure at screening or baseline.
- •Type I diabetes mellitus, or poorly controlled Type II diabetes mellitus.
- •Malignancy and/or chemotherapy within 1 year prior to screening, other than basal cell carcinoma. Malignancies more than 1 year may not preclude participation and will be reviewed on a case-by-case basis by the Somerset Pharmaceuticals, Inc., medical monitor.
- •Any skin condition (e.g., eczema, psoriasis, dyshydrosis) that might interfere with application and adherence of the STS.
- •Known or suspected hypersensitivity to selegiline or other MAO inhibitors.
- •Any significant immunological, pulmonary, hematologic, endocrine and/or metabolic disease or disorder or severe or acute medical illness, that is, metastatic cancer, brain tumors, decompensated cardiac, hepatic or renal failure.
- •Neurological disorders including delirium, history of head trauma, movement disorders, dementia, multiple sclerosis, stroke, within the past 6 months preceding the study.
- •Any central nervous system disorder including Alzheimer's disease, Parkinson's disease, epilepsy, or cerebrovascular disease.
- •Any psychiatric disorders (except personality disorders).
- •Any mood disorder including MDD which is current or relapsed over the past three years.
- •Any conditions that may cause depression including endocrinopathies other than diabetes, lymphoma, pancreatic cancer.
- •Any other illness or disorder that in the opinion of the Investigator would place the subject at significant risk or any inability to follow the requirements of the study regarding maintaining scheduled visits or patch applications.
- •Use of any medication listed below within five half-lives prior to baseline. A longer period of time may be specifically noted for certain medications as indicated:
- •All contraindicated medications (see Section 7.1.4.3)
- •Psychotropic medication, including centrally active anticholinergics, anticonvulsants, antiparkinsonian agents, fluoxetine (5 weeks), MAOIs (2 weeks), antipsychotics (oral - 60 days; intramuscular - 10 weeks), anxiolytics, vasodilators (exception: Viagra is permitted), cerebral enhancers (acetylcholinesterase inhibitors), psychostimulants, lithium carbonate, nootropics, reserpine, methyldopa (within 30 days), ergot preparations.
- •Sympathomimetic drugs, e.g., amphetamines, methylphenidate, dopamine, epinephrine, norepinephrine, over-the-counter (OTC) and prescription nasal decongestants (with the exception of nasal steroids), oral or inhaled sympathomimetic bronchodilators (e.g., albuterol [Proventil], Serevent) and appetite suppressants.
- •Any serotonergic drug including sumatriptan succinate (Imitrex), zolmitriptan (Zomig), cyproheptadine (Periactin), methysergide (Sansert) or other agonists or antagonists of serotonin receptors.
- •Meperidine (Demerol), or other opioids.
- •R(-)tryptophan, metoclopramide.
- •St. John's wort / hypericum within two (2) weeks and other herbal supplements
- •Dietary supplements containing tyramine and/or ephedrine.
- •Presence of an Axis-II disorder that makes it unlikely that the subject will be compliant.
- •Presence or history of bipolar disorder or psychotic disorder.
- •Serious risk of suicide.
- •History of substance abuse, including alcohol abuse as defined by DSM-IV criteria, within the past 12 months.
- •Current use of tobacco products.
研究组 & 干预措施
A
Active Comparator
EMSAM 6mg
干预措施: EMSAM (Selegiline Transdermal System) 6mg (Drug)
B
Active Comparator
EMSAM (Selegiline Transdermal System) 12mg
干预措施: EMSAM (Selegiline Transdermal System) 12mg (Drug)
结局指标
主要结局
Dose Proportionality of PK parameters and EMSAM release characteristics.
时间窗: 33 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)Essential ThrombocythaemiaNCT00413634Shire24
已完成
不适用
esomeprazole in pre-eclampsiapre-eclampsiaPACTR201908560004686faculty pf medicine suez canal university80
招募中
不适用
Caelyx PK.pharmacokineticscaelyxcancerNL-OMON23804Erasmus University Medical Center34
终止
1 期
Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058Pulmonary Arterial HypertensionNCT04991194Bial - Portela C S.A.61
已完成
4 期
The Effect of Age on the Median Effective Dose (ED50) of Intranasal Dexmedetomidine for Rescue Sedation Following Failed Sedation With Oral Chloral Hydrate During Magnetic Resonance ImagingAgedDrugDose-Response RelationshipNCT02253199Guangzhou Women and Children's Medical Center120